REGN5678
REGN5678 is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Success Metrics
Phase Distribution
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
0.0%
0 of 0 finished
0.0%
0 ended early
4
trials recruiting
4
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Clinical Trials (4)
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4